Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on In-Situ Hybridization Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on In-Situ Hybridization Industry
  • 1.7 COVID-19 Impact: In-Situ Hybridization Market Trends

    • 2 Global In-Situ Hybridization Quarterly Market Size Analysis

    • 2.1 In-Situ Hybridization Business Impact Assessment - COVID-19
      • 2.1.1 Global In-Situ Hybridization Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global In-Situ Hybridization Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global In-Situ Hybridization Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, In-Situ Hybridization Headquarters and Area Served
    • 3.3 Date of Key Players Enter into In-Situ Hybridization Market
    • 3.4 Key Players In-Situ Hybridization Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on In-Situ Hybridization Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Radioactive isotopes
      • 1.4.2 Non-radioactive labels
    • 4.2 By Type, Global In-Situ Hybridization Market Size, 2019-2021

    5 Impact of Covid-19 on In-Situ Hybridization Segments, By Application

    • 5.1 Overview
      • 5.5.1 Cancer Diagnosis
      • 5.5.2 Immunology
      • 5.5.3 Neuroscience
      • 5.5.4 Cytology
      • 5.5.5 Infectious Diseases
    • 5.2 By Application, Global In-Situ Hybridization Market Size, 2019-2021
      • 5.2.1 By Application, Global In-Situ Hybridization Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Abbott Laboratories
      • 7.1.1 Abbott Laboratories Business Overview
      • 7.1.2 Abbott Laboratories In-Situ Hybridization Quarterly Revenue, 2020
      • 7.1.3 Abbott Laboratories In-Situ Hybridization Product Introduction
      • 7.1.4 Abbott Laboratories Response to COVID-19 and Related Developments
    • 7.2 F. Hoffmann-La Roche
      • 7.2.1 F. Hoffmann-La Roche Business Overview
      • 7.2.2 F. Hoffmann-La Roche In-Situ Hybridization Quarterly Revenue, 2020
      • 7.2.3 F. Hoffmann-La Roche In-Situ Hybridization Product Introduction
      • 7.2.4 F. Hoffmann-La Roche Response to COVID-19 and Related Developments
    • 7.3 Leica Biosystems Nussloch
      • 7.3.1 Leica Biosystems Nussloch Business Overview
      • 7.3.2 Leica Biosystems Nussloch In-Situ Hybridization Quarterly Revenue, 2020
      • 7.3.3 Leica Biosystems Nussloch In-Situ Hybridization Product Introduction
      • 7.3.4 Leica Biosystems Nussloch Response to COVID-19 and Related Developments
    • 7.4 Agilent Technologies
      • 7.4.1 Agilent Technologies Business Overview
      • 7.4.2 Agilent Technologies In-Situ Hybridization Quarterly Revenue, 2020
      • 7.4.3 Agilent Technologies In-Situ Hybridization Product Introduction
      • 7.4.4 Agilent Technologies Response to COVID-19 and Related Developments
    • 7.5 Thermo Fisher Scientific
      • 7.5.1 Thermo Fisher Scientific Business Overview
      • 7.5.2 Thermo Fisher Scientific In-Situ Hybridization Quarterly Revenue, 2020
      • 7.5.3 Thermo Fisher Scientific In-Situ Hybridization Product Introduction
      • 7.5.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments
    • 7.6 Merck
      • 7.6.1 Merck Business Overview
      • 7.6.2 Merck In-Situ Hybridization Quarterly Revenue, 2020
      • 7.6.3 Merck In-Situ Hybridization Product Introduction
      • 7.6.4 Merck Response to COVID-19 and Related Developments
    • 7.7 PerkinElmer
      • 7.7.1 PerkinElmer Business Overview
      • 7.7.2 PerkinElmer In-Situ Hybridization Quarterly Revenue, 2020
      • 7.7.3 PerkinElmer In-Situ Hybridization Product Introduction
      • 7.7.4 PerkinElmer Response to COVID-19 and Related Developments
    • 7.8 Exiqon A/S
      • 7.8.1 Exiqon A/S Business Overview
      • 7.8.2 Exiqon A/S In-Situ Hybridization Quarterly Revenue, 2020
      • 7.8.3 Exiqon A/S In-Situ Hybridization Product Introduction
      • 7.8.4 Exiqon A/S Response to COVID-19 and Related Developments
    • 7.9 BioGenex Laboratories
      • 7.9.1 BioGenex Laboratories Business Overview
      • 7.9.2 BioGenex Laboratories In-Situ Hybridization Quarterly Revenue, 2020
      • 7.9.3 BioGenex Laboratories In-Situ Hybridization Product Introduction
      • 7.9.4 BioGenex Laboratories Response to COVID-19 and Related Developments
    • 7.10 Advanced Cell Diagnostics
      • 7.10.1 Advanced Cell Diagnostics Business Overview
      • 7.10.2 Advanced Cell Diagnostics In-Situ Hybridization Quarterly Revenue, 2020
      • 7.10.3 Advanced Cell Diagnostics In-Situ Hybridization Product Introduction
      • 7.10.4 Advanced Cell Diagnostics Response to COVID-19 and Related Developments
    • 7.11 Bio SB
      • 7.11.1 Bio SB Business Overview
      • 7.11.2 Bio SB In-Situ Hybridization Quarterly Revenue, 2020
      • 7.11.3 Bio SB In-Situ Hybridization Product Introduction
      • 7.11.4 Bio SB Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of In-Situ Hybridization, including the following market information:
      Global In-Situ Hybridization Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global In-Situ Hybridization Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global In-Situ Hybridization Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global In-Situ Hybridization Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Abbott Laboratories, F. Hoffmann-La Roche, Leica Biosystems Nussloch, Agilent Technologies, Thermo Fisher Scientific, Merck, PerkinElmer, Exiqon A/S, BioGenex Laboratories, Advanced Cell Diagnostics, Bio SB, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Radioactive isotopes
      Non-radioactive labels

      Based on the Application:
      Cancer Diagnosis
      Immunology
      Neuroscience
      Cytology
      Infectious Diseases

      Buy now